Ashwagandha for Anxious Kids: Why Pediatric Evidence Doesn't Exist Yet

Ashwagandha (Withania somnifera) is one of the fastest-growing supplement categories of the 2020s, and pediatric versions — gummies, syrups, "calm kids" formulas — have followed the adult market into U.S. retail. The marketing pitches stress relief and improved sleep for anxious children. The clinical literature in children, however, is so thin that the most accurate description is: there is essentially no pediatric evidence base.

What Has Been Studied in Adults

Adult trials of standardized ashwagandha extracts (KSM-66 and Shoden are the most common) have shown reductions in self-reported stress and salivary cortisol vs placebo, with effect sizes that have varied considerably across replication. Sleep onset latency reductions of 10–20 minutes have been reported in some adult trials. The adult evidence is best characterized as "promising for stress and sleep, but smaller than the marketing implies." None of this evidence directly transfers to pediatric populations.

Pediatric Trials: Almost None

A PubMed search through April 2026 returns only a handful of pediatric ashwagandha studies. The most-cited is Choudhary 2017, an open-label study in 30 children aged 8–14 with deficient memory and concentration. The trial used 250 mg twice daily for 4 months and reported improvements in attention scores. It was not placebo-controlled, was small, and was sponsored by the extract manufacturer. There is no published RCT of ashwagandha for childhood anxiety.

Why "Adult Data Should Apply" Is Wrong Here

Adult-to-pediatric extrapolation works in narrow circumstances: well-characterized pharmacokinetics, established safety profile, and a similar disease mechanism. Ashwagandha has none of these in children. The herb's main bioactives (withanolides) have not had pediatric pharmacokinetic studies. Long-term safety data in growing humans does not exist. Ashwagandha modulates the hypothalamic-pituitary-adrenal axis — the same axis that drives pubertal development — and the consequences of long-term modulation in adolescents are unstudied.

The Thyroid Concern

Multiple case reports and the 2018 Sharma trial have shown that ashwagandha increases thyroid hormone levels (T3, T4) and can shift subclinical hypothyroid patients into normal range. This is potentially useful in adults with subclinical hypothyroidism, but in children the same effect can produce iatrogenic hyperthyroidism, especially in adolescent girls who already have a higher background rate of thyroid disease. There are no pediatric trials measuring thyroid impact.

Liver Injury Signal

The U.S. Drug-Induced Liver Injury Network has reported a small but increasing series of ashwagandha hepatotoxicity cases in adults, mostly in 2019–2024. The American College of Gastroenterology now lists ashwagandha among herbal supplements associated with idiosyncratic liver injury. There are isolated pediatric case reports but no incidence data — a child's smaller body mass and developing liver may amplify rather than reduce this signal.

The Practical Bottom Line

Pediatric anxiety has effective interventions: cognitive-behavioral therapy is first-line, with SSRIs and exposure therapy as established second-line options. Sleep hygiene, family-based interventions, and treatment of anxiety disorders are evidence-based. Ashwagandha for an anxious child is, in 2026, an unknown intervention substituting for known ones. There is no responsible evidence-based recommendation for it in this population.